Just caught something interesting about what legendary investor Stanley Druckenmiller is quietly positioning himself in right now. The guy who made his fortune managing George Soros's money and ran Duquesne Capital for 30 consecutive winning years—never a losing year, mind you—is making some bold moves through his family office. And his recent portfolio moves are worth paying attention to.

One of his biggest bets is Natera, a genetic testing company that's become a serious player in women's health and cancer diagnostics. This stock represents over 13% of his holdings, and there's a reason he's backing it hard. The company is currently unprofitable on paper, but here's where it gets interesting: the unit economics are actually working. Revenue's expected to grow at high-teens rates through 2027, and more importantly, gross margins keep expanding—hit 64.9% in Q3 2025 versus 61.8% the year before. That's the kind of margin expansion that usually signals pricing power.

What really caught my eye is their oncology test business. It grew 54% in Q3 and now represents nearly a quarter of total tests. Their Signatera blood test for detecting residual cancer is the crown jewel here. The cash flow picture is what makes Stanley Druckenmiller's conviction make sense though—the company's already cash-generative despite losses, has recurring revenue (cancer survivors keep testing), and Wall Street models show free cash flow jumping from $103 million in 2025 to $282 million by 2027. That's a scalable business if I've ever seen one.

Now, his second major position is Taiwan Semiconductor, which is up 80% over the past year riding the AI wave. Everyone's chasing this story—Alphabet, Amazon, they're all throwing massive capital at AI infrastructure. The problem? Taiwan Semi's CEO basically admitted on the earnings call that AI demand was robust while everything else saw only mild recovery. Translation: the entire valuation depends on AI staying hot.

Here's the kicker that Stanley Druckenmiller and other smart money are probably wrestling with: capital spending just hit $101 billion and is expected to climb even higher over the next three years. The company's carrying a heavier capex burden for customers, which means free cash flow margin expansion is going to be squeezed. That's a real constraint investors need to factor in.

So what's the takeaway? Stanley Druckenmiller's split between Natera and Taiwan Semi tells you something about how top investors are thinking right now. One's a high-growth story with improving unit economics and real cash generation. The other's a solid play on an unstoppable trend, but with structural margin pressures ahead. Both positions make sense, but they're playing different games.